Ms. hebr. oct. 100 - Minḥat Yehuda

Vorbesitzer: Abraham Merzbacher

A sketch of the Talmud : the world renowned collection of Jewish traditions

by Isidor Kalisch

Biographical sketch of Dr. K. Kohler

by Max J. Kohler

Min hametzar : psaume 118 de F. Halévy

transcr. pour le pianoforte par Gotthard Wöhler

Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy

OBJECTIVES Pre-antiretroviral therapy (ART) inflammation and coagulation activation predict clinical outcomes in HIV-positive individuals. We assessed whether pre-ART inflammatory marker levels predicted the CD4 count response to ART. METHODS Analyses were based on data from the Strategic Management of Antiretroviral Therapy (SMART) trial, an international trial evaluating continuous vs. interrupted ART, and the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial, evaluating three first-line ART regimens with at least two drug classes. For this analysis, participants had to be ART-naïve or off ART at randomization and (re)starting ART and have C-reactive protein (CRP), interleukin-6 (IL-6) and D-dimer measured pre-ART. Using random effects linear models, we assessed the association between each of the biomarker levels, categorized as quartiles, and change in CD4 count from ART initiation to 24 months post-ART. Analyses adjusted for CD4 count at ART initiation (baseline), study arm, follow-up time and other known confounders. RESULTS Overall, 1084 individuals [659 from SMART (26% ART naïve) and 425 from FIRST] met the eligibility criteria, providing 8264 CD4 count measurements. Seventy-five per cent of individuals were male with the mean age of 42 years. The median (interquartile range) baseline CD4 counts were 416 (350-530) and 100 (22-300) cells/μL in SMART and FIRST, respectively. All of the biomarkers were inversely associated with baseline CD4 count in FIRST but not in SMART. In adjusted models, there was no clear relationship between changing biomarker levels and mean change in CD4 count post-ART (P for trend: CRP, P = 0.97; IL-6, P = 0.25; and D-dimer, P = 0.29). CONCLUSIONS Pre-ART inflammation and coagulation activation do not predict CD4 count response to ART and appear to influence the risk of clinical outcomes through other mechanisms than blunting long-term CD4 count gain.

Sēfer talmîd ṣaḥqān mûsārî : ... ḥibbûr qāṭān ... mē-haw-wikkûaḥ še-hāyā bên 2 talmîdîm ôhāvîm we-rāʿîm mē-ḥāmat haṣ-ṣāḥôq ... ʿim marʿê māqôm mit-Tôrā nevîʿîm û-Ktûvîm û-min-hat-Talmûd... der gilernṭi und bikerṭi špilr ...

[Jehuda Arje aus Modena]

Divrê niṣṣāḥôn min han-nevî'îm le-daʿat šeb-bā māšî'aḥ w-Κûaʿ han-nôṣerî hû ham-māšîaḥ

Digitalisat der Ausg. London, 1819

Mišnāyôt : ʿim pêrûš Melô qaf naḥat

ḥibbērô ... Šnî'ûr Faybš ... be-niqqûd hā-ôtiyyô û-ve-haʿttāqā aškenazzît

Daiṭše iberzetzung min sēfer Tehillîm

fun ... Mōše Dessoi

Minḥā ḥadāšā : ʿim šemen le-minḥā ; anhang tzu Pele yôʿēṣ ; kurtzgefasṭe dinim meliḥe ḥale we-hadloke miṭ einige ... divre musar

bearbeiẹtṭ und heroisgegeben mimmenî ... Yehûdā Kōhēn Qrôys

Sēfer Śîaḥ Yiṣḥāq : we-hû min Pele yôʿēṣ ; has-sēfer haz-ze neʿttāq mik-kammā sefārîm ... û-vî-feraṭ min has-sēfer Pele yôʿēṣ ... gam neʿttāq bô kammā dinîm ... ; oif ivri-ṭaiṭš ...

ham-maʿttîq Yiṣḥāq B. ... Efrayim Fišel Hamburger mi- ... Qrâqā

Sēfer Minḥā ṭehôrā : kôlēl dînîm mē-hilkôt melîḥā, niddā, ḥallā we-hadlāqā bi-lešôn askenazzî ṣaḥ we-nāqî ... le-tôʿelet benôt Yiśrā'ēl

... Zalmān B. ... Mōše Bônhard

Sippûrê mûsār : minê qedem

naie bearbeiṭung fon Dawid Oṭṭenzozer